A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults

Inclusion Criteria:

• Healthy males or non-pregnant, non-lactating healthy females.

• Participants who are overtly healthy as determined by medical evaluation includingmedical history, physical examination, vital signs, triplicate 12-lead ECG,screening clinical laboratory profiles (hematology, clinical chemistry, coagulation,and urinalysis), as deemed by the Investigator or designee.

• Female participants of childbearing potential and male participants must followprotocol-specified contraception guidance

• BMI within the range of 18.0 to 32.0 kg/m2 (inclusive) and a minimum body weight of 50.0 kg at screening.

Exclusion Criteria:

• History of clinically significant cardiovascular, respiratory, hepatic, renal,gastrointestinal, endocrinological, hematological, neurological, psychiatric orother disorders; constituting a risk when taking the study intervention; orinterfering with the interpretation of data.

• History of meningococcal infection.

• History of additional risk factors for Torsades de Pointes (eg, heart failure,hypokalemia, family history of Long QT syndrome).

• History of unexplained, recurrent infection, or infection requiring treatment withsystemic antibiotics within 14 days prior to Period 1 Day 1.

• History of significant multiple and/or severe allergies (hay fever is allowed unlessit is active), including significant hypersensitivity reactions to commonly usedantibacterial agents, including beta-lactams, penicillin, amoxicillin,aminopenicillin, fluoroquinolones (specifically including ciprofloxacin),cephalosporins, and carbapenems, which in the opinion of the Investigator would makeit difficult to provide empiric antibiotic therapy or treat an active infection.

• Diseases or conditions or previous procedures known to interfere with theabsorption, distribution, metabolism, or excretion of drugs.

• History of malignancy within 5 years prior to screening, with the exception ofnonmelanoma skin cancer or carcinoma in situ of the cervix that has been treatedwith no evidence of recurrence.

• Known hepatic or biliary abnormalities (including participants with Gilbert'ssyndrome).